Helix BioPharma announced the Trial Steering Committee reviewed safety data from the first dosing cohort of the Company’s LDOS003 study.
Helix BioPharma (TSX:HBP) announced the Trial Steering Committee (TSC) reviewed safety data from the first dosing cohort of the Company’s LDOS003 study.
As quoted in the press release:
No serious adverse events or dose limiting toxicities were observed. TSC recommended that Helix begin enrollment of patients into the second dosing cohort.
LDOS003 is a Phase II, open-label, randomized study of immunoconjugate L-DOS47 in combination with vinorelbine and cisplatin as compared to vinorelbine and cisplatin alone in patients with lung adenocarcinoma.
“We are very encouraged that the first dosing cohort of this L-DOS47 phase II study in combination with chemotherapy has been completed,” said Heman Chao, Helix’s Chief Executive Officer. “We look forward to receiving more data as we advance the L-DOS47 development program.”